Read by QxMD icon Read


Jan P Nicolay, Marion Wobser
Primär kutane B-Zell-Lymphome (PCBCL) beschreiben reifzellige lymphoproliferative Erkrankungen der B-Zell-Reihe, die primär die Haut betreffen. Die Biologie und der klinische Verlauf der einzelnen PCBCL-Subtypen variieren untereinander stark und unterscheiden sich grundsätzlich von primär nodalen und systemischen B-Zell-Lymphomen. Primär kutane Marginalzonenlymphome (PCMZL) und primäre kutane follikuläre Keimzentrumslymphome (PCFCL) werden auf Grund ihres unkomplizierten Verlaufs und ihrer exzellenten Prognose zu den indolenten PCBCL gezählt...
December 2016: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
Iris Wieser, Michael T Tetzlaff, Carlos A Torres Cabala, Madeleine Duvic
Primär kutane CD30(+) lymphoproliferative Erkrankungen zählen zu der zweit häufigsten Gruppe der kutanen T-Zell-Lymphome (CTCL) und umfassen die Krankheitsbilder der lymphomatoiden Papulose (LyP) und des primär kutanen anaplastischen großzelligen Lymphoms (cALCL). Beide Erkrankungen haben klinische, histopathologische und molekulare Gemeinsamkeiten und repräsentieren ein Spektrum von kutanen CD30(+) lymphoproliferativen Erkrankungen. Man kann LyP vom cALCL anhand des Zusammenspiels von klinischen und histopathologischen Befunden unterscheiden...
August 2016: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
Seung Bae Yoon, In Seok Lee, Ha Ni Lee, Eunyoung Kim, Woohyeon Kim, Han Hee Lee, Bo-In Lee, Myung-Gyu Choi, Seung Eun Jung, Byung Ock Choi, Gyeong Sin Park, Seok-Goo Cho
OBJECTIVE: According to lymphoma guidelines, gastric diffuse large B cell lymphoma (DLBCL) patients should undergo regular computed tomography (CT) and/or positron emission tomography (PET) examinations to assess treatment response. Endoscopic examinations are not indicated in the guidelines. The aim of this study was to investigate the utility of endoscopic examinations during and after treatment for DLBCL. METHODS: We reviewed the patients diagnosed with gastric DLBCL at Seoul St...
September 2016: Scandinavian Journal of Gastroenterology
Vincent Ribrag, Serge Koscielny, Jacques Bosq, Thibaut Leguay, Olivier Casasnovas, Luc-Mathieu Fornecker, Christian Recher, Hervé Ghesquieres, Franck Morschhauser, Stéphane Girault, Steven Le Gouill, Mario Ojeda-Uribe, Clara Mariette, Jerome Cornillon, Guillaume Cartron, Veronique Verge, Catherine Chassagne-Clément, Hervé Dombret, Bertrand Coiffier, Thierry Lamy, Hervé Tilly, Gilles Salles
BACKGROUND: Short intensive chemotherapy is the standard of care for adult patients with Burkitt's leukaemia or lymphoma. Findings from single-arm studies suggest that addition of rituximab to these regimens could improve patient outcomes. Our objective was to test this possibility in a randomised trial. METHODS: In this randomised, controlled, open-label, phase 3 trial, we recruited patients older than 18 years with untreated HIV-negative Burkitt's lymphoma (including Burkitt's leukaemia) from 45 haematological centres in France...
June 11, 2016: Lancet
Silke Hellmich, Natalie Schreiber, Birgit Fath, Michael Hallek
The Competence Network Malignant Lymphomas (KML), founded in 1999 at the initiative of the Federal Ministry of Education and Research (BMBF), brings together interdisciplinary medical and scientific expertise in research on malignant lymphomas. The network helps to release synergies in evidence-based clinical research and contributes to the accelerated transfer of advances in knowledge gained from therapeutic studies for the health care of lymphoma patients. During the regular BMBF funding period (1999-2009) individual sub-projects were hived off, such as the Cochrane Haematological Malignancies Group (CHMG) or the Scientific Institute of Haematologists and Oncologists in Private Practice (WINHO GmbH)...
April 2016: Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
Jan P Nicolay, Moritz Felcht, Kai Schledzewski, Sergij Goerdt, Cyrill Géraud
Das Sézary-Syndrom, die leukämische Variante des kutanen T-Zell-Lymphoms, stellt immer noch eine Erkrankung mit vielen ungelösten Fragen sowie einer sehr ungünstigen Prognose dar. In jüngeren Forschungsarbeiten wurde jedoch eine Vielzahl an fehlregulierten molekularen Signalwegen identifiziert, die zur malignen Transformation und Therapieresistenz von Sézary-Zellen (SC) beitragen. Im Hinblick auf die T-Zell-Entwicklung repräsentieren SC entweder naive T-Zellen, T-Effektor-Gedächtniszellen oder zentrale T-Gedächtniszellen...
March 2016: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
Maja V Maraldo, Francesco Giusti, Ivan R Vogelius, Michael Lundemann, Marleen A E van der Kaaij, Safaa Ramadan, Bart Meulemans, Michel Henry-Amar, Berthe M P Aleman, John Raemaekers, Paul Meijnders, Elisabeth C Moser, Hanneke C Kluin-Nelemans, Pierre Feugier, Olivier Casasnovas, Catherine Fortpied, Lena Specht
BACKGROUND: Cardiovascular disease after treatment is an important concern in cancer survivors. However, knowledge of cardiotoxicity is limited by the retrospective nature of data, which often does not contain details of treatment exposure. To facilitate individual risk counselling of patients, we aimed to quantify the effect of anthracyclines, vinca-alkaloids, and radiotherapy on the risk of cardiovascular disease in patients treated for Hodgkin's lymphoma. METHODS: In 2009-10, a Life Situation Questionnaire (LSQ) was distributed to patients by mail to assess late-onset effects of Hodgkin's lymphoma treatment in patients who were included in nine successive European Organisation for Research and Treatment of Cancer (EORTC) and the Groupe d'Etude des Lymphomes de l'Adulte (GELA, now renamed LYSA) randomised trials between 1964 and 2004...
November 2015: Lancet Haematology
Mathias Rummel, Ulrich Kaiser, Christina Balser, Martina Stauch, Wolfram Brugger, Manfred Welslau, Norbert Niederle, Christoph Losem, Hans-Peter Boeck, Eckhart Weidmann, Ulrich von Gruenhagen, Lothar Mueller, Michael Sandherr, Lars Hahn, Julia Vereshchagina, Frank Kauff, Wolfgang Blau, Axel Hinke, Juergen Barth
BACKGROUND: Fludarabine-based chemoimmunotherapy with rituximab is frequently used in patients with indolent and mantle-cell lymphomas who relapse after alkylating chemotherapy. We aimed to compare the efficacy and safety of rituximab with bendamustine or fludarabine in patients with relapsed, indolent, non-Hodgkin lymphoma and mantle-cell lymphoma. METHODS: For this randomised, non-inferiority, open-label, phase 3 trial, we recruited patients from 55 centres in Germany, who were subsequently randomised centrally according to prespecified randomisation lists with permuted blocks of randomly variable block size to rituximab (375 mg/m(2), day 1) plus either bendamustine (90 mg/m(2), days 1 and 2) or fludarabine (25 mg/m(2), days 1-3) every 28 days for a maximum of six 28-day cycles...
January 2016: Lancet Oncology
Agnès Ruskoné-Fourmestraux, Tamara Matysiak-Budnik, Bettina Fabiani, Pascale Cervera, Hedia Brixi, Karine Le Malicot, Isabelle Nion-Larmurier, Jean-Fançois Fléjou, Christophe Hennequin, Laurent Quéro
BACKGROUND: In gastric MALT lymphomas persisting after Helicobacter pylori (H. pylori) eradication, a treatment by moderate-dose radiotherapy (RT) has been proposed but its efficacy has not been confirmed in large prospective series with long term endoscopic follow-up. METHOD: Patients with localised gastric MALT lymphoma persisting after H. pylori eradication were offered moderate-dose RT (30Gy, 2Gy/fraction) and followed with annual endoscopies. All biopsies before and after RT were reviewed by a committee of pathologists...
October 2015: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
Gandhi Damaj, Sarah Ivanoff, Diane Coso, Loïc Ysaebert, Sylvain Choquet, Caroline Houillier, Anne Parcelier, Wajed Abarah, Zora Marjanovic, Rémy Gressin, Reda Garidi, Momar Diouf, Anne-Claire Gac, Jehan Dupuis, Xavier Troussard, Franck Morschhauseur, Hervé Ghesquières, Carole Soussain
The purpose of our study is to determine the outcome of patients with systemic non-Hodgkin lymphoma presenting with neurologic localization at diagnosis, as well as the impact of consolidation in terms of high-dose therapy followed by autologous stem cell transplantation. Newly diagnosed non-Hodgkin lymphoma patients with concomitant systemic and neurological involvement at diagnosis were included in this study. Sixty patients (37 males; 25 females) were included. Median age was 61 years (23-85 years). Histological subtype was mainly diffuse large B-cell lymphoma (n = 54; 90%)...
September 2015: Haematologica
C Patte, F Traore, M El Kababri, C Bouda, G Leverger, M-A Raquin, M Harif
No abstract text is available yet for this article.
May 2015: Archives de Pédiatrie: Organe Officiel de la Sociéte Française de Pédiatrie
Bruce Shiramizu, Stanton Goldman, Lynette Smith, Melissa Agsalda-Garcia, Paul Galardy, Sherrie L Perkins, J Kimble Frazer, Warren Sanger, James R Anderson, Thomas G Gross, Howard Weinstein, Lauren Harrison, Matthew J Barth, Lara Mussolin, Mitchell S Cairo
Patient-specific primers from 10 children/adolescents with Burkitt leukaemia (BL) ± central nervous system disease who were treated with French-British-American/Lymphome Malins de Burkitt 96 C1 plus rituximab were developed from diagnostic blood/bone marrow. Minimal residual disease (MRD) was assessed by real-time polymerase chain reaction at the end of induction (EOI) and consolidation (EOC). Seventy per cent (7/10) and 71% (5/7) were MRD-positive at EOI and EOC, respectively, with no disease recurrences...
August 2015: British Journal of Haematology
Semra Paydas
Diffuse large B cell lymphoma (DLBCL) of the stomach is a heterogenous disease. There are tumors without histological evidence of mucosa-associated lymphoid tissue (MALT) lymphoma, which are classified as pure or de novo DLBCL and those with evidence of MALT, which are classified as DLBCL (MALT). The association between Helicobacter pylori (H. pylori) and gastric MALT lymphoma and remission with H. pylori eradication was shown in the 1990s. In recent years, scientists from Taiwan and others have shown that high-grade gastric lymphomas may be dependent on H...
April 7, 2015: World Journal of Gastroenterology: WJG
Alexander Kreuter, Tina van Eijk, Percy Lehmann, Matthias Fischer, Thomas Horn, Chalid Assaf, Gaston Schley, Rudolf Herbst, Ivonne Kellner, Christiane Weisbrich, Julia Hyun, Ulrike Wieland, Max Schlaak, Albert Rübben, Kerstin Lommel
HINTERGRUND: Nach Ausschöpfung von klassischen Behandlungsverfahren wie Chemo- und Strahlentherapie existieren bei ausgedehnten Hauttumoren oder Hautmetastasen nur wenige Optionen einer lokalen Tumorkontrolle. In diesen Fällen kann die Elektrochemotherapie als Therapiealternative in Erwägung gezogen werden. PATIENTEN UND METHODIK: Im Rahmen einer retrospektiven Studie wurden klinische Charakteristika, Ansprechen und Bedingungen des Ansprechens sowie Nebenwirkungen von 56 Patienten untersucht, die an sechs deutschen Hautkliniken behandelt wurden...
April 2015: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
Sonja Grunewald, Alexander Jank
Mit Einführung zahlreicher neuer, überwiegend biologischer Systemtherapien in der Dermatologie stellt sich im klinischen Alltag regelmäßig die Frage, inwieweit eine Anwendung bei Kinderwunsch oder in Schwangerschaft und Stillzeit möglich ist und welche Risiken ggf. damit verbunden sind. Seriöse Informationen liefern neben Fachinformation und Roter Liste Datenbanken wie die des Pharmakovigilanz- und Beratungszentrums für Embryonaltoxikologie der Charité Berlin ( oder eine Literaturrecherche (z...
April 2015: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
Anne Jourdain, Anne Auperin, Véronique Minard-Colin, Nathalie Aladjidi, Josef Zsiros, Carole Coze, Virginie Gandemer, Yves Bertrand, Guy Leverger, Christophe Bergeron, Jean Michon, Catherine Patte
To describe relapsed B-cell lymphoma or leukemia in children/adolescents treated with a "Lymphomes Malins B" regimen and their outcome and to identify prognostic factors for survival, we studied relapses in the LMB89, 96 and 2001 studies of the Société Française d'Oncologie Pédiatrique (Société Française des Cancers de l'Enfant). Therapeutic guidelines at relapse were to obtain a second complete remission and to consolidate the remission with high-dose chemotherapy followed by autologous stem-cell transplantation...
June 2015: Haematologica
Thierry Jo Molina, Danielle Canioni, Christiane Copie-Bergman, Christian Recher, Josette Brière, Corinne Haioun, Françoise Berger, Christophe Fermé, Marie-Christine Copin, Olivier Casasnovas, Catherine Thieblemont, Tony Petrella, Karen Leroy, Gilles Salles, Bettina Fabiani, Franck Morschauser, Nicolas Mounier, Bertrand Coiffier, Fabrice Jardin, Philippe Gaulard, Jean-Philippe Jais, Hervé Tilly
PURPOSE: To determine whether any tumor biomarkers could account for the survival advantage observed in the LNH 03-2B trial among patients with diffuse large B-cell lymphoma (DLBCL) and low-intermediate risk according to the International Prognostic Index when treated with dose-intensive rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (R-ACVBP) compared with standard rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisone (R-CHOP). PATIENTS AND METHODS: Using immunohistochemistry, expression of CD10, BCL6, MUM1, MYC, and BCL2 and coexpression of MYC/BCL2 were examined...
December 10, 2014: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Stanton Goldman, Lynette Smith, Paul Galardy, Sherrie L Perkins, John Kimble Frazer, Warren Sanger, James R Anderson, Thomas G Gross, Howard Weinstein, Lauren Harrison, Bruce Shiramizu, Matthew Barth, Mitchell S Cairo
Children and adolescents with Burkitt Lymphoma (BL) and combined central nervous system (CNS) and bone marrow involvement still have a poor prognosis with chemotherapy alone. We therefore investigated in children and adolescents with bone marrow (≥25% blasts) and/or CNS-positive Burkitt lymphoma the chemoimmunotherapy combination of rituximab (375 mg/m(2) ) and the standard chemotherapy arm of our previously reported French-American-British (FAB) Lymphome Malins de Burkitt (LMB) 96 trial. Central pathological and cytogenetic characterization was also performed...
November 2014: British Journal of Haematology
Jian Guan, Peter Gluckman, Panzao Yang, Geoff Krissansen, Xueying Sun, Yongzhi Zhou, Jingyuan Wen, Gemma Phillips, Paul R Shorten, Chris D McMahon, Graeme C Wake, Wendy H K Chan, Mark F Thomas, April Ren, Steve Moon, Dong-Xu Liu
The homeostasis of insulin-like growth factor-1 (IGF-1) is essential for metabolism, development and survival. Insufficient IGF-1 is associated with poor recovery from wounds whereas excessive IGF-1 contributes to growth of tumours. We have shown that cyclic glycine-proline (cGP), a metabolite of IGF-1, can normalise IGF-1 function by showing its efficacy in improving the recovery from ischemic brain injury in rats and inhibiting the growth of lymphomic tumours in mice. Further investigation in cell culture suggested that cGP promoted the activity of IGF-1 when it was insufficient, but inhibited the activity of IGF-1 when it was excessive...
2014: Scientific Reports
Matthew J Maurer, Hervé Ghesquières, Jean-Philippe Jais, Thomas E Witzig, Corinne Haioun, Carrie A Thompson, Richard Delarue, Ivana N Micallef, Frédéric Peyrade, William R Macon, Thierry Jo Molina, Nicolas Ketterer, Sergei I Syrbu, Olivier Fitoussi, Paul J Kurtin, Cristine Allmer, Emmanuelle Nicolas-Virelizier, Susan L Slager, Thomas M Habermann, Brian K Link, Gilles Salles, Hervé Tilly, James R Cerhan
PURPOSE: Studies of diffuse large B-cell lymphoma (DLBCL) are typically evaluated by using a time-to-event approach with relapse, re-treatment, and death commonly used as the events. We evaluated the timing and type of events in newly diagnosed DLBCL and compared patient outcome with reference population data. PATIENTS AND METHODS: Patients with newly diagnosed DLBCL treated with immunochemotherapy were prospectively enrolled onto the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource (MER) and the North Central Cancer Treatment Group NCCTG-N0489 clinical trial from 2002 to 2009...
April 1, 2014: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"